文献类型：期刊文献

英文题名：A DNA Origami-Based Uricase Nanovehicle for Reducing Blood Uric Acid Levels

作者：Liu, Yi-Shan[1];Shi, Wen-Jia[1];Li, Hua-Dong[2,3];Liu, Yue[1];Li, Chao-Qiang[4];Ma, Pei-Qiang[1];Ye, Bang-Ce[1,4]

机构：[1]East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Lab Biosyst & Microanal, Shanghai 200237, Peoples R China;[2]Shanghai Jiao Tong Univ, Renji Hosp, Inst Mol Med, Sch Med, Shanghai 200127, Peoples R China;[3]Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Key Lab Nucl Acid Chem & Nanomed, Shanghai 200127, Peoples R China;[4]Shihezi Univ, Sch Chem & Chem Engn, Shihezi 832000, Xinjiang, Peoples R China

年份：2025

卷号：25

期号：51

起止页码：17763

外文期刊名：NANO LETTERS

收录：;EI(收录号：20255219795097);WOS:【SCI-EXPANDED(收录号:WOS:001636473500001)】；

基金：This work was jointly supported by the National Key Research and Development Program of China (Grant 2024YFA0917100), the National Natural Science Foundation of China (Grant 22134003), the Natural Science Foundation of Shanghai (Grant 25ZR1403002), and the Fundamental Research Funds for the Central Universities. The authors thank the Research Center of Analysis and Test of East China University of Science and Technology for the help with the characterization experiments. The authors thank the staff members of the Integrated Laser Microscopy System/Molecular Imaging System at the National Facility for Protein Science in Shanghai (NFPS) (Shanghai Advanced Research Institute, Chinese Academy of Sciences) for AFM data collection and analysis.

语种：英文

外文关键词：uricase; DNA origami; albumin-binding domain; hyperuricemia treatment

摘要：Exogenous uricase (UOx) has been employed in hyperuricemia treatment, but its foreign protein nature induces an immunogenicity risk and short circulatory half-life in vivo, limiting clinical application. To address these limitations, we developed a DNA origami-based UOx nanovehicle (UOxNV) with a double-layer structure. UOx was site-specifically anchored on a six-helix bundle DNA scaffold, while an albumin-binding domain peptide (ABD) on the outer layer selectively bound serum albumin (SA) to form a protective SA shell. As a proof of concept, we demonstrated UOxNV had enhanced serum stability and a weakened inflammatory response in comparison with those of free UOx. An extended circulatory half-life and a sustained serum uric acid-lowering efficacy were further confirmed in a mouse model. This study presents a novel strategy utilizing DNA nanotechnology to overcome key limitations in current UOx therapeutics, advancing biomedical nanotechnology applications.